Image
Recommendation
Risk-reducing strategies #3
In women with breast cancer with a confirmed germline mutation (e.g. BRCA 1/2) that predisposes to an increased risk of ovarian/fallopian tube cancer, refer to a gynaecological oncologist for discussion of the benefits and risks of bilateral salpingo-oophorectomy (BSO).
Discuss risk-reducing salpingo-oophorectomy with women diagnosed with breast cancer with a BRCA1/2 mutation around the age of 40 years or when child-bearing is complete to improve overall survival and substantially decrease the risk of ovarian/fallopian tube cancer
Body of evidence can be trusted to guide practice in most situations
How this guidance was developed
This recommendation was adapted from the CA 2014 guidelines (Australia). The source recommendation was based on a systematic review of the evidence conducted to April 2012 and was graded 'B' (using NHMRC methods) by the source guideline authors. The source recommendation was adapted by removing the specification of age and gender in the patient population. The lack of certainty of the evidence regarding BSO among women with breast cancer who are BRCA1/2 mutation carriers and reduced risk of breast cancer and reduced breast cancer mortality was noted.
Related guidance by topic
Risk-reducing strategies #3
Recommendation
In women with breast cancer with a confirmed germline mutation (e.g. BRCA 1/2) that predisposes to an increased risk of ovarian/fallopian tube cancer, refer to a gynaecological oncologist for discussion of the benefits and risks of bilateral salpingo-oophorectomy (BSO).
Principles in action
Supportive care
Image
Communication
This recommendation was adapted from the CA 2014 guidelines (Australia). The source recommendation was based on a systematic review of the evidence conducted to April 2012 and was graded 'B' (using NHMRC methods) by the source guideline authors. The source recommendation was adapted by removing the specification of age and gender in the patient population. The lack of certainty of the evidence regarding BSO among women with breast cancer who are BRCA1/2 mutation carriers and reduced risk of breast cancer and reduced breast cancer mortality was noted.
Related guidance by topic
Image
Genetic considerations
Image
